Based on pathological information, such as histologic type, grade, ER status, PR status, HER-2 status, Ki-67 index, tumor size, and axillary lymph node status, we routinely select a particular treatment for a patient with early breast cancer [13]. The gene discussed is ERBB2; the disease is breast carcinoma.